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BACKGROUND
Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has 
a devastating outcome. We compared myeloablative CD34+ selected autologous hemato-
poietic stem-cell transplantation with immunosuppression by means of 12 monthly infu-
sions of cyclophosphamide in patients with scleroderma.
METHODS
We randomly assigned adults (18 to 69 years of age) with severe scleroderma to undergo 
myeloablative autologous stem-cell transplantation (36 participants) or to receive cyclo-
phosphamide (39 participants). The primary end point was a global rank composite 
score comparing participants with each other on the basis of a hierarchy of disease 
features assessed at 54 months: death, event-free survival (survival without respiratory, 
renal, or cardiac failure), forced vital capacity, the score on the Disability Index of the 
Health Assessment Questionnaire, and the modified Rodnan skin score.
RESULTS
In the intention-to-treat population, global rank composite scores at 54 months showed 
the superiority of transplantation (67% of 1404 pairwise comparisons favored transplan-
tation and 33% favored cyclophosphamide, P = 0.01). In the per-protocol population 
(participants who received a transplant or completed ≥9 doses of cyclophosphamide), the 
rate of event-free survival at 54 months was 79% in the transplantation group and 50% 
in the cyclophosphamide group (P = 0.02). At 72 months, Kaplan–Meier estimates of 
event-free survival (74% vs. 47%) and overall survival (86% vs. 51%) also favored trans-
plantation (P = 0.03 and 0.02, respectively). A total of 9% of the participants in the trans-
plantation group had initiated disease-modifying antirheumatic drugs (DMARDs) by 54 
months, as compared with 44% of those in the cyclophosphamide group (P = 0.001). 
Treatment-related mortality in the transplantation group was 3% at 54 months and 6% 
at 72 months, as compared with 0% in the cyclophosphamide group.
CONCLUSIONS
Myeloablative autologous hematopoietic stem-cell transplantation achieved long-term 
benefits in patients with scleroderma, including improved event-free and overall survival, 
at a cost of increased expected toxicity. Rates of treatment-related death and post-trans-
plantation use of DMARDs were lower than those in previous reports of nonmyeloabla-
tive transplantation. (Funded by the National Institute of Allergy and Infectious Dis-
eases and the National Institutes of Health; ClinicalTrials.gov number, NCT00114530.)
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Scleroderma with internal-organ involvement (diffuse cutaneous systemic sclerosis) is a devastating autoimmune dis-
order. Despite advances in management, mortality 
driven by pulmonary involvement has not changed 
in 40 years.1-3 Although disease-modifying anti-
rheumatic drugs (DMARDs) and biologics have 
been studied, none have shown lasting benefit, 
and only cyclophosphamide given for 12 months 
has shown short-term benefit as compared with 
placebo.4-6 For many patients, scleroderma is a 
fatal disease.
Pilot studies of autologous hematopoietic stem-
cell transplantation in scleroderma showed im-
provement in skin sclerosis and stabilization of 
pulmonary function.7-10 Two randomized trials 
of nonmyeloablative transplantation also showed 
benefit11,12; however, neither trial changed clini-
cal practice in the United States, in part owing 
to concerns about durability of response and the 
safety of transplantation.13 Our trial (Scleroderma: 
Cyclophosphamide or Transplantation [SCOT]) 
tests a different therapeutic approach: myelo-
ablation with total-body irradiation followed by 
reconstitution with a CD34+ selected autograft 
versus cyclophosphamide. We hypothesized that 
myeloablative transplantation would result in bet-
ter long-term outcomes than cyclophosphamide 
treatment. Participants were followed closely 
over a period of 4.5 years to assess safety and 
durability of remission. The primary end point, 
assessed at 54 months, was a global rank com-
posite score based on a hierarchy of disease 
features.
Me thods
Trial Design, Interventions, and Oversight
This randomized, open-label, phase 2 trial was 
conducted at 26 sites (Table S1 in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org). Randomization was per-
formed on a 1:1 basis and stratified according to 
site, with the difference in the number of partici-
pants in the two treatment groups constrained to 
two or fewer at each site.14 The trial ended when 
the last participant completed the month 54 evalu-
ation, with a maximum follow-up to 72 months. 
After an event of respiratory, renal, or cardiac 
failure occurred (i.e., event-free survival was not 
achieved), clinic visits ended but telephone con-
tacts continued to month 54. Death was investi-
gated with the use of public records, as needed.
Hematopoietic progenitors were mobilized with 
granulocyte colony-stimulating factor (G-CSF); 
after leukapheresis and CD34+ cell enrichment, 
the autologous product was cryopreserved.15 Frac-
tionated total-body irradiation (800 cGy), cyclo-
phosphamide (120 mg per kilogram of body 
weight), and equine antithymocyte globulin 
(90 mg per kilogram) were given as previously 
reported.9,16 Pulmonary and renal shields limited 
organ exposure to a target of 200 cGy.17 After 
conditioning, participants received CD34+ cells 
(median, 5.6×106 per kilogram; interquartile 
range, 3.8 to 6.0) and post-transplantation care 
with G-CSF, glucocorticoids, lisinopril, and anti-
infective agents including acyclovir, which was 
given for 1 year (Table S2 in the Supplementary 
Appendix).9,18 In the cyclophosphamide group, 
an initial intravenous dose of 500 mg per square 
meter of body-surface area was followed by 11 
monthly infusions of 750 mg per square meter 
with mesna prophylaxis.
A data and safety monitoring board appoint-
ed by the National Institute of Allergy and Infec-
tious Diseases, the trial sponsor, provided over-
sight. An independent end-point review committee 
whose members were aware of the trial-group 
assignments verified causes of death and verified 
events of respiratory, renal, or cardiac failure. 
Institutional review boards at each site approved 
the protocol, and Rho (Chapel Hill, NC) held and 
analyzed the data. Members of the steering com-
mittee (Table S1 in the Supplementary Appen-
dix) designed the trial, vouch for its adherence 
to the protocol, and attest to the accuracy and 
completeness of the data and analyses as speci-
fied in the protocol and statistical analysis plan, 
which are available at NEJM.org. The trial data 
are accessible from ImmPort (www . immport . org) 
in study SDY1039 (DOI: 10.21430/M3SM4LTLH). 
The first author wrote the initial draft, and all 
the coauthors reviewed the manuscript and 
agreed to publication. All the participants in the 
trial provided written informed consent.
Participants
Adults (18 to 69 years of age) with scleroderma 
(American College of Rheumatology 1995 crite-
ria) for 5 years or less with pulmonary or renal 
involvement were eligible. Pulmonary involvement 
required active interstitial lung disease (as deter-
mined by bronchoalveolar cell composition or 
ground-glass opacities on computed tomography 
of the chest) plus either a forced vital capacity 
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(FVC) or a diffusing capacity of the lung for 
carbon monoxide (DLco) of less than 70% of the 
predicted value. Renal involvement required pre-
vious scleroderma-related renal disease. Key ex-
clusion criteria were active gastric antral vascular 
ectasia, a DLco of less than 40% of the predicted 
value, an FVC of less than 45% of the predicted 
value, a left ventricular ejection fraction of less 
than 50%, a creatinine clearance of less than 40 ml 
per minute, pulmonary arterial hypertension, or 
more than 6 months of previous treatment with 
cyclophosphamide.19,20
Evaluations and End Points
Participants were evaluated monthly through 
year 1, then approximately quarterly through 
year 5. Serial pulmonary-function testing was 
performed in the same laboratory, with DLco 
(Crapo–Morris calculation) corrected for anemia. 
Rheumatologists were certified to assess the 
modified Rodnan skin score (range, 0 [normal] 
to 51 [severe skin thickening]); minimally im-
portant differences are 3.2 to 5.3 points. Scales 
are more fully detailed in Section S1 of Methods 
in the Supplementary Appendix.21,22
The primary end point was the global rank 
composite score at 54 months. The global rank 
composite score is an analytic tool that accounts 
for multiple disease manifestations simultane-
ously but does not measure disease activity or 
severity. It reflects how participants compare 
with one another on the basis of a hierarchy of 
ordered outcomes: death, event-free survival (sur-
vival without respiratory, renal, or cardiac fail-
ure), FVC, the score on the Disability Index of 
the Health Assessment Questionnaire (HAQ-DI; 
range, 0 to 3, with higher scores indicating more 
disability), and the modified Rodnan skin score 
(Section S1 of Methods in the Supplementary 
Appendix). Participants who were alive at 54 
months rank higher than those who died; those 
who survived event-free rank higher than those 
who had an event, and so forth down the hier-
archy (Sections S2 and S3 of Methods in the 
Supplementary Appendix). With the assumption 
that transplant recipients would have worse 
early outcomes but could fare better long-term 
than participants in the comparison group, the 
global rank composite score is intentionally con-
structed to treat early and late deaths (or events 
of organ failure) as equal, irrespective of timing. 
Variables that were used to define an event in-
cluded death, respiratory failure (decrease from 
baseline of >30% in percent predicted DLco or 
>20% in percent predicted FVC) (Section S2 of 
Methods in the Supplementary Appendix), renal 
failure (long-term dialysis or renal transplanta-
tion), or cardiac failure (clinical congestive heart 
failure or left ventricular ejection fraction <30%).
The lowest three components of the global 
rank composite score are ordinal. They were 
defined by improvement (increase of ≥10% in 
the percentage of the predicted FVC, decrease of 
>0.4 in the HAQ-DI score, or decrease of ≥25% 
in the modified Rodnan skin score, as compared 
with baseline values), no change (neither improve-
ment nor worsening), or worsening (decrease 
from baseline of ≥10% in the percentage of the 
predicted FVC, increase of >0.4 in the HAQ-DI 
score, or increase of ≥25% in the modified Rod-
nan skin score, as compared with baseline values).
Secondary end points included individual com-
ponents of the global rank composite score, 
measures of disease progression, and quality of 
life. Safety end points included treatment-related 
death, death from any cause, treatment-related 
toxic effects, infections, and hematologic engraft-
ment. Deaths, cancers, and disease-progression 
events that occurred after an event of respiratory, 
renal, or cardiac failure were tracked as second-
ary end points but were not reported as adverse 
events.
Statistical Analysis
The trial was originally designed for 226 par-
ticipants, with event-free survival as the primary 
end point. Low accrual prompted amendments, 
first to broaden entry criteria, then, ultimately, 
to reduce the sample size by changing the pri-
mary end point to the global rank composite 
score. Power for the new design with 114 par-
ticipants was estimated by simulations at 93% 
for a two-sided test with an alpha level of 0.05. 
Assumptions for the simulations were guided by 
data on similarly treated patients involved in 
previous studies.4,9 No SCOT data informed the 
redesign process (details in Section S3 of Meth-
ods in the Supplementary Appendix). With con-
tinued slow accrual but without reviewing effi-
cacy results, the data and safety monitoring 
board recommended stopping randomization at 
75 participants.
For ordinal end points, including the global 
rank composite score, the Wilcoxon signed-rank 
test was used for comparisons; the van Elteren 
extension of the Wilcoxon signed-rank test was 
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used for stratified analyses.23,24 The effect size 
for the Wilcoxon signed-rank test is reported as 
the percent of all possible pairs between the two 
groups that favor transplantation (or cyclophos-
phamide). Fisher’s exact test was used for dichoto-
mous events, including death and event-free sur-
vival at 54 and 48 months; the Mantel–Haenszel 
chi-square test was used for stratified analysis. 
Kaplan–Meier survival curves were compared 
with the use of log-rank tests. The data and 
safety monitoring board reviewed four prespeci-
fied futility analyses that included an ability to 
stop for efficacy with P<0.0001, leaving an alpha 
level of 0.0496 for the primary intention-to-treat 
analysis of the global rank composite score at 
54 months after randomization. The intention-to-
treat population was defined as all the partici-
pants who had undergone randomization. Second-
ary analyses are presented for the per-protocol 
population, defined as participants who received 
a transplant or completed nine or more doses of 
cyclophosphamide. Secondary analyses are sup-
portive; P values were not adjusted for multiple 
comparisons. Safety results are summarized for 
all the participants who initiated treatment. Analy-
ses used SAS software, version 9.3 or higher.
 R esult s
 Trial Population
From July 2005 through September 2011, a total 
of 75 of the 205 screened patients underwent 
randomization. Patients who did not meet entry 
criteria or who were denied insurance coverage 
accounted for the majority of screening failures 
(Fig. S1 in the Supplementary Appendix). In the 
transplantation group (36 participants), 34 initi-
Figure 1. Participant Milestones.
Milestones for each participant assigned to undergo 
myeloablative hematopoietic stem-cell transplantation 
(Panel A) or to receive cyclophosphamide (Panel B) are 
depicted from the time of informed consent. Organ fail-
ure refers to respiratory, renal, or cardiac failure. For early 
withdrawals from the trial, death was investigated with 
the use of site and public records. In Panels A and B, 
each black hash mark represents a clinical evaluation 
with pulmonary-function tests at the transplantation 
center. In Panel B, the asterisk identifies a participant 
who gave consent more than 12 months before random-
ization. The vertical dashed line at 54 months indicates 
participant status at the time of the primary end point.
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ated mobilization and 33 received a transplant. 
In the cyclophosphamide group (39 participants), 
37 initiated treatment; 32 received 12 doses and 
34 received 9 or more doses. Of the 75 partici-
pants, 46 (27 in the transplantation group and 
19 in the cyclophosphamide group) completed 
the trial, 14 (3 in the transplantation group and 
11 in the cyclophosphamide group) died during 
the trial, and 15 (6 in the transplantation group 
and 9 in the cyclophosphamide group) withdrew 
prematurely (Fig. 1, and Fig. S1 in the Supple-
mentary Appendix).
Baseline characteristics reflected severe sclero-
derma: the mean modified Rodnan skin score 
was 30, the mean DLco was 53% of the pre-
dicted value, and 97% of the participants had 
Characteristic
Transplantation 
(N = 36)
Cyclophosphamide 
(N = 39)
Total 
(N = 75)
Mean age — yr 44.9±10.9 46.9±10.4 45.9±10.6
Female sex — no. (%) 19 (53) 29 (74) 48 (64)
Race — no. (%)†
White 29 (81) 31 (79) 60 (80)
Black 2 (6) 4 (10) 6 (8)
Other 5 (14) 4 (10) 9 (12)
Smoking status — no. (%)
Current or former smoker 14 (39) 10 (26) 24 (32)
Never smoked 22 (61) 29 (74) 51 (68)
Mean duration of scleroderma before 
 randomization — mo
25.1±12.9 29.0±16.0 27.1±14.6
DMARD use in previous 6 mo — no. (%) 26 (72) 25 (64) 51 (68)
Previous use of cyclophosphamide — no. (%) 8 (22) 17 (44) 25 (33)
Lung involvement — no. (%) 36 (100) 37 (95) 73 (97)
Mean modified Rodnan skin score‡ 28.5±8.7 30.8±10.5 29.7±9.7
Mean FVC — % of predicted value 74.5±14.8 73.8±17.0 74.1±15.9
Mean DLco — % of predicted value 53.9±7.6 52.7±8.2 53.3±7.9
Mean left ventricular ejection fraction — %§ 61.0±6.1 59.9±4.3 60.4±5.2
Mean creatinine clearance — ml/min 122.8±41.7 124.9±54.3 123.9±48.3
Mean ESR — mm/hr¶ 29.8±26.5 32.2±24.9 31.1±25.4
Mean SF-36 physical component score‖ 29.5±9.2 28.9±9.5 29.2±9.3
Mean SF-36 mental component score‖ 44.7±10.7 44.6±9.9 44.6±10.2
Mean HAQ-DI score** 1.2±0.6 1.4±0.9 1.3±0.8
*  Plus–minus values are means ±SD. Although the between-group differences for sex, smoking status, and previous use of 
cyclophosphamide appear potentially clinically relevant, no P values for comparisons between the two groups were less 
than 0.05, on the basis of t-tests for numerical variables and Fisher’s exact test for categorical variables. P = 0.06 for sex, 
0.39 for smoking status, and 0.06 for previous use of cyclophosphamide. Additional data on participant characteristics 
are provided in Table S3 in the Supplementary Appendix. DLco denotes diffusing capacity of the lung for carbon monox-
ide, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate, and FVC forced vital capacity.
†  Race was reported by the participant.
‡  Modified Rodnan skin scores range from 0 (normal) to 51 (severe skin thickening).
§  Data were available for 36 participants in the transplantation group and 37 in the cyclophosphamide group.
¶  Data were available for 29 participants in the transplantation group and 34 in the cyclophosphamide group.
‖  Scores on the physical and mental components of the 36-Item Short Form General Health Survey (SF-36) range from 
0 to 100, with higher scores indicating better quality of life. Data were available for 35 participants in the transplanta-
tion group and 35 in the cyclophosphamide group.
**  Scores on the Disability Index of the Health Assessment Questionnaire (HAQ-DI) range from 0 to 3, with higher 
scores indicating more disability. Data were available for 35 participants in the transplantation group and 38 in the 
cyclophosphamide group.
Table 1. Demographic and Clinical Characteristics at Baseline (Intention-to-Treat Population).*
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pulmonary involvement (Table 1, and Table S3 in 
the Supplementary Appendix). The two groups had 
similar characteristics except that the cyclophos-
phamide group had more female participants, 
participants who had never smoked, and partici-
pants who had previously used cyclophosphamide 
than the transplantation group. Reasons for the 
imbalance are unknown.
Efficacy
In the intention-to-treat population, the global 
rank composite score favored transplantation at 
54 months (prespecified primary end point) and 
48 months (key secondary end point); the percent 
of 1404 (36 × 39) pairwise comparisons favoring 
transplantation over cyclophosphamide was 67% 
versus 33% at 54 months (P = 0.01) and 68% ver-
Variable Transplantation Cyclophosphamide P Value†
Intention-to-treat population
No. of participants 36 39
Primary efficacy end point: GRCS at 54 mo‡
Median (range) 17.0 (−58 to 52) −6.0 (−58 to 52) 0.01
Percent of favorable pairwise comparisons 66.6 33.4
GRCS at 48 mo‡
Median (range) 20.0 (−58 to 55) −8.0 (−58 to 55) 0.008
Percent of favorable pairwise comparisons 67.6 32.4
Death or respiratory, renal, or cardiac failure — no. (%)
By 54 mo 10 (28) 20 (51) 0.06
By 48 mo 10 (28) 20 (51) 0.06
Death from any cause — no. (%)
By 54 mo 6 (17) 11 (28) 0.28
By 48 mo 6 (17) 11 (28) 0.28
Treatment-related death — no. (%)§
By 54 mo 1 (3) 0 0.48
By 48 mo 1 (3) 0 0.48
Per-protocol population
No. of participants 33 34
GRCS at 54 mo‡
Median (range) 16.0 (−56 to 46) −11.0 (−56 to 46) 0.004
Percent of favorable pairwise comparisons 70.1 29.9
GRCS at 48 mo‡
Median (range) 17 (−56 to 49) −13.0 (−56 to 49) 0.003
Percent of favorable pairwise comparisons 71.3 28.7
Death or respiratory, renal, or cardiac failure — no. (%)
By 54 mo 7 (21) 17 (50) 0.02
By 48 mo 7 (21) 17 (50) 0.02
Death from any cause — no. (%)
By 54 mo 3 (9) 8 (24) 0.19
By 48 mo 3 (9) 8 (24) 0.19
Treatment-related death — no. (%)§
By 54 mo 1 (3) 0 0.49
By 48 mo 1 (3) 0 0.49
Table 2. Efficacy End Points (Intention-to-Treat and Per-Protocol Populations).*
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sus 32% at 48 months (P = 0.008) (Table 2 and 
Fig. 2). In the per-protocol population, the per-
cent of comparisons favoring transplantation on 
the global rank composite score was 70% versus 
30% at 54 months (P = 0.004) and 71% versus 
29% at 48 months (P = 0.003) (Table 2).
Results of prespecified secondary analyses of 
event-free survival corroborate the composite-
score results. In the per-protocol population, the 
rate of event-free survival at 54 months was 79% 
in the transplantation group and 50% in the cyclo-
phosphamide group (P = 0.02) (Table 2). Most 
events of organ failure were respiratory failure 
(in 5 participants in the transplantation group 
and 13 in the cyclophosphamide group); renal 
failure occurred in 1 participant in the trans-
plantation group, and cardiac failure occurred in 
1 participant in the cyclophosphamide group. In 
the per-protocol analysis, Kaplan–Meier estimates 
for the treatment groups begin to separate in 
favor of transplantation at approximately 2 years. 
At 72 months, the rate of event-free survival was 
74% in the transplantation group and 47% in the 
cyclophosphamide group (P = 0.03), and the rate 
of overall survival was 86% and 51%, respec-
tively (P = 0.02) (Fig. 2). Results of the intention-
to-treat analysis were consistent with these find-
ings (Fig. 2).
In the per-protocol population at 54 months, 
the percentage of participants who had initiated 
DMARDs was lower in the transplantation group 
than in the cyclophosphamide group (9% vs. 
44%, P = 0.001) (Table 2). No participants in the 
transplantation group had had congestive heart 
failure or pulmonary arterial hypertension, as 
compared with 12% and 15%, respectively, of 
the participants in the cyclophosphamide group 
(P = 0.04 and P = 0.02, respectively). Both among 
participants who had survived event-free (at 54 
months) and among those who had died or had 
had organ failure (at last assessment), the trans-
plantation group was more likely than the cyclo-
phosphamide group to show improvements on 
prespecified secondary clinical end points, in-
cluding the modified Rodnan skin score (100% 
vs. 82% among those who survived event-free 
Variable Transplantation Cyclophosphamide P Value†
Disease-progression event by 54 mo — no. (%)
Initiated DMARDs¶ 3 (9) 15 (44) 0.001
New or worsening arrhythmia 6 (18) 4 (12) 0.46
Congestive heart failure leading to treatment 0 4 (12) 0.04
Clinically significant pericardial effusion 2 (6) 0 0.15
Pulmonary arterial hypertension 0 5 (15) 0.02
Scleroderma-related renal crisis 0 1 (3) 0.32
Myositis 1 (3) 0 0.31
*  The intention-to-treat population was defined as all the participants who had undergone randomization. The per-proto-
col population was defined as participants who received a transplant or completed nine or more doses of cyclophos-
phamide. Because pulmonary and renal toxic effects are expected and reversible during the recovery period after autolo-
gous stem-cell transplantation, events of respiratory failure or renal failure were not evaluated in either treatment group 
until month 14 and month 8, respectively.
†  For the global rank composite score (GRCS), P values are based on the Wilcoxon signed-rank test. For death with or 
without respiratory, renal, or cardiac failure, P values are based on Fisher’s exact test. For disease-progression events 
by 54 months, P values are based on Pearson’s chi-square test.
‡  The range for the GRCS is sample specific and depends on the number of participants included in the analysis and the 
number of ties in score. The higher the score, the better the participant’s performance relative to others in the sample. 
Percent refers to the percent of pairwise comparisons between participants that favored transplantation or cyclophos-
phamide. For example, in the intention-to-treat analysis at 54 months, with 36 participants in the transplantation group 
and 39 in the cyclophosphamide group, there were 1404 possible pairwise comparisons (i.e., 36 × 39). In 935 of the 
1404 paired comparisons (66.6%), the global rank composite score favored transplantation.
§  “Related” includes events that were deemed to be probably or definitely related to the treatment regimen or CD34+ he-
matopoietic progenitor cells, as reported by the site investigator. By 72 months, there were 2 deaths (6%) in the trans-
plantation group and 0 in the cyclophosphamide group (intention-to-treat and per-protocol populations).
¶  By 24 months, a total of three participants (9%) in the transplantation group and seven participants (21%) in the cyclo-
phosphamide group had initiated disease-modifying antirheumatic drugs (DMARDs).
Table 2. (Continued.)
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and 71% vs. 29% among those who had died or 
had had organ failure), the HAQ-DI score (65% 
vs. 35% and 29% vs. 0%), and the score on the 
physical component of the 36-Item Short Form 
General Health Survey (SF-36) (73% vs. 35% and 
14% vs. 0%) (Fig. S2 in the Supplementary Ap-
pendix).
In post hoc analyses controlling individually 
for between-group imbalances at baseline with 
respect to sex, smoking status, and previous use 
of cyclophosphamide, outcomes favored trans-
plantation over cyclophosphamide on the global 
rank composite score at 54 months. Within indi-
vidual strata, with the exception of current or 
former smokers, pairwise comparisons favored 
transplantation (range, 56 to 77% of compari-
sons), with the greatest benefit noted for partici-
pants who had never smoked (P≤0.04 for all 
three stratified analyses) (Table S4 in the Sup-
plementary Appendix). Findings for covariate-
adjusted analyses of event-free survival at 54 
months were consistent with these findings 
(Table S4 in the Supplementary Appendix). Post 
hoc sensitivity analyses that used different as-
sumptions to handle missing data on event-free 
survival at 54 months in computing the global 
rank composite score also support the primary 
end-point analysis (Table S5 in the Supplemen-
tary Appendix).
Safety, Infection, and Engraftment
A total of 21 deaths occurred over a period of 
72 months (Table 3 and Fig. 1). Deaths after 54 
months did not contribute to the primary end 
point. Of the 7 participants in the transplanta-
tion group who died, 3 did not receive the trans-
plant; 2 died of treatment-related causes, at months 
17 and 70, after a diagnosis of the myelodysplas-
tic syndrome; and 2 had already had an event of 
respiratory, renal, or cardiac failure. No trans-
plant recipient died within a year after transplan-
tation. The 14 participants in the cyclophospha-
mide group who died included 3 who received 
five or fewer doses and 7 who had already had 
an event of respiratory, renal, or cardiac failure. 
No deaths were attributable directly to cyclophos-
phamide.
Over a period of 72 months, the percentage of 
participants who had serious adverse events was 
lower in the cyclophosphamide group than in the 
transplantation group (51% and 74%, respectively). 
However, after we accounted for the duration of 
follow-up, the rate of serious adverse events in 
person-years was 0.38 in the transplantation 
group and 0.52 in the cyclophosphamide group 
(P = 0.08) (Table S6 in the Supplementary Appen-
dix). In the transplantation group, 96% of serious 
adverse events occurred in the first 26 months, 
as compared with 71% of serious adverse events 
in the cyclophosphamide group (Fig. S3 in the 
Supplementary Appendix). The percentage of par-
ticipants who had an adverse event of grade 3 or 
more was higher in the transplantation group 
than in the cyclophosphamide group (100% vs. 
Figure 2 (facing page). Primary and Key Secondary 
 Outcomes.
Panel A shows the distribution of global rank composite 
scores (GRCSs) at month 54 in the intention-to-treat 
population according to treatment group. Black repre-
sents deaths (score, −58). Remaining scores range 
from −30 to 52 on a red (worst)–yellow–green (best) 
scale. P = 0.01 for the comparison between treatment 
groups (Wilcoxon signed-rank test). Panel B shows 
components of the GRCS at month 54 for participants 
in the intention-to-treat population. Each row represents 
an individual participant. In the first column, black indi-
cates death at month 54 and white indicates alive. In the 
second column, dark gray indicates an event of respira-
tory, renal, or cardiac failure; light gray indicates no event 
of respiratory, renal, or cardiac failure; and blank indicates 
that event-free survival (EFS) status could not be eval-
uated at month 54. In columns 3 through 5 (percent of 
predicted forced vital capacity [FVC], score on the Dis-
ability Index of the Health Assessment Questionnaire 
[HAQ-DI], and modified Rodnan skin score [mRSS]), 
green represents improvement, yellow no change, and 
red worsening, as compared with baseline values. All 
deaths (black) are treated equally. The figure shows 
the last available assessment before death, but boxes 
are faded to indicate that these steps in the hierarchy 
were not used for GRCS evaluation. Similarly, if EFS 
status could not be evaluated (blank), the outcome 
status for the last available assessments is shown as 
faded, and participants were ranked on the basis of 
survival status alone. Panel C shows the Kaplan–Meier 
estimates of overall survival and event-free survival in 
the intention-to-treat population (all the participants 
who had undergone randomization), and Panel D shows 
such estimates in the per-protocol population (partici-
pants who received a transplant or completed ≥9 doses 
of cyclophosphamide). In Panels C and D, the vertical 
dashed line represents the 54-month time point.
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84%); the event rate per person-year was also 
higher (2.0 vs. 1.2, P<0.001). In the transplanta-
tion group, 95% of adverse events of grade 3 or 
more occurred during the first 26 months, of 
which 50% were expected cytopenias (Tables S6 
and S7 and Fig. S3 in the Supplementary Appen-
dix). We noted cancers in four participants: three 
in the transplantation group (one had papillary 
thyroid cancer and two had the myelodysplastic 
syndrome) and one in the cyclophosphamide 
group (who had breast cancer).
The rate of infections (of any grade) per per-
son-year were similar in the two groups (0.75 in 
the transplantation group and 0.79 in the cyclo-
phosphamide group) (Tables S8 through S10 in 
the Supplementary Appendix). However, the rate 
of infections of grade 3 or more per person-year 
was higher in the transplantation group than 
in the cyclophosphamide group (0.21 vs. 0.13, 
P = 0.09) (Table S6 in the Supplementary Appen-
dix), with 92% of the events occurring in the 
first 26 months (Table S7 in the Supplementary 
Appendix). Varicella zoster infection occurred in 
13 participants (12 in the transplantation group 
and 1 in the cyclophosphamide group, P<0.001). 
All but two zoster infections occurring in trans-
plant recipients developed 1 to 4 years after trans-
plantation; one episode was disseminated and 
none were life-threatening. Five cases of cyto-
megalovirus reactivation occurred, all more than 
Group and Time from 
Randomization to Death Site-Reported Cause of Death Completed Treatment
Cyclophosphamide group
1.7 Mo Pulmonary embolism No (2 doses of cyclophosphamide)
6.6 Mo Respiratory failure No (5 doses of cyclophosphamide)
18.2 Mo Scleroderma Yes
24.5 Mo Scleroderma* Yes
25.4 Mo Septic shock Yes
27.2 Mo Pulmonary hypertension Yes
29.3 Mo Respiratory* Yes
29.3 Mo Respiratory failure* Yes
32.3 Mo Unknown cause† No (0 doses of cyclophosphamide)
35.7 Mo Respiratory failure Yes
39.4 Mo Arrhythmia* Yes
54.7 Mo‡ Infection* Yes
68.9 Mo‡ Progression of systemic sclerosis*† Yes
69.8 Mo‡ Sepsis*† Yes
Transplantation group
2.4 Mo Unknown cause No (no mobilization, conditioning, or  
transplantation)
2.6 Mo Pulmonary alveolar hemorrhage No (no conditioning or transplantation)
9.3 Mo Unknown cause No (no mobilization, conditioning, or  
transplantation)
16.9 Mo Enterococcal meningitis§ Yes
23.9 Mo Respiratory* Yes
24.1 Mo Metabolic*† Yes
69.9 Mo‡ Acute myeloid leukemia§ Yes
*  The participant had had an event of respiratory, renal, or cardiac failure before death.
†  Death was identified through site contact or public records after participant withdrawal or trial completion.
‡  Deaths after 54 months were not counted in the primary end-point analyses.
§  Death occurred after a diagnosis of the myelodysplastic syndrome.
Table 3. Deaths during the 72-Month Trial Period (Intention-to-Treat Population).
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2.5 months after transplantation, with no herpes 
simplex or Epstein–Barr virus infections noted.
One transplant recipient had inadequate stem-
cell mobilization with G-CSF and required cyclo-
phosphamide. All transplant recipients had had 
sustained engraftment with neutrophil recovery 
by days 8 to 12 and final platelet transfusion by 
days 6 to 23.
Discussion
In the SCOT trial, treatment of severe sclero-
derma with myeloablative therapy and CD34+ 
selected autologous hematopoietic stem-cell trans-
plantation led to superior long-term outcomes as 
compared with cyclophosphamide. The result of 
the intention-to-treat analysis of the global rank 
composite score at 54 months (the primary end 
point) was conclusive even after accounting for 
between-group imbalances at baseline. Secondary 
per-protocol analyses of global rank composite 
scores and traditional end points (overall sur-
vival, event-free survival, modified Rodnan skin 
score, and DMARD use) further corroborated 
this result.
Our results confirm the findings of the Autolo-
gous Stem Cell Transplantation International 
Scleroderma (ASTIS) trial, including the advan-
tage for patients who had never smoked.12 In the 
ASTIS trial, scleroderma relapse (defined as the 
need for DMARD therapy) was observed in 22% 
of the participants at 12 to 24 months after non-
myeloablative transplantation. In the SCOT trial, 
only 9% of transplant recipients had initiated 
DMARDs by 24 months (the rate was also 9% at 
54 months). Evidence that patients with sclero-
derma could have significant improvement and 
remain free of DMARDs supports transplanta-
tion as a treatment for this serious disease. After 
transplantation, the burden of severe adverse 
events was considerable but limited in onset, 
with 96% of serious adverse events occurring in 
the first 26 months after transplantation. Over-
all infection rates were similar in the two groups 
with one exception: varicella zoster infection de-
veloped in 12 of 33 transplant recipients (36%). 
Other toxic effects were consistent with those in 
studies of transplantation in other diseases.
Although the global rank composite score has 
not been used in studies of scleroderma, similar 
approaches have gained acceptance in trials of 
other diseases.25-29 The global rank composite 
score is not a clinical measure but rather an 
analytic approach that compares every participant 
in a study with every other participant on the 
basis of a predefined hierarchy of outcomes — 
in this case, outcomes specific for severe sclero-
derma.1,4,9,12 Objective components (death, event-
free survival, and FVC) were scored at a higher 
priority than more subjective measures (HAQ-DI 
score and modified Rodnan skin score). The va-
lidity of this approach is supported by the more 
traditional secondary analyses. Use of the global 
rank composite score permitted the simultaneous 
assessment of multiple disease features as part 
of an efficient trial design.
Complications of autologous transplantation 
for autoimmune disease include treatment-related 
deaths, cancers, and infections.30 Historically, in-
fections are the most common causes of death; 
infections tend to cluster in the first month after 
transplantation and decrease thereafter.31,32 Al-
though scleroderma is associated with an in-
creased risk of cancer, chemotherapy and irra-
diation are also associated with increased cancer 
risk.33,34 Patients who are exposed to total-body 
irradiation are at increased risk for secondary 
cancers over a lifetime. Additional follow-up will 
be needed to quantify the risk of late cancer in 
patients with scleroderma who are treated with 
total-body irradiation as well as long-term out-
comes of the trial.
Transplant-related mortality of 3% at 54 months 
and 6% at 72 months in the SCOT trial was 
lower than that previously reported.12,35 No deaths 
were observed during the first year (95% confi-
dence interval [CI], 0% to 9.7%). In the ASTIS 
trial, treatment-related mortality among 75 non-
myeloablative transplant recipients was 10.7% 
(95% CI, 4.5 to 19.0) during the first year.12 Dif-
ferences in treatment-related mortality could be 
due to differences in disease characteristics at 
trial entry: none of the SCOT participants had 
cardiac involvement or pulmonary arterial hyper-
tension, and fewer had ever smoked. The non-
myeloablative ASTIS trial used high doses of cy-
clophosphamide for both mobilization (4 g per 
square meter, or approximately 100 mg per kilo-
gram) and transplantation (200 mg per kilogram). 
A similar high-dose regimen of cyclophosphamide 
in conjunction with transplantation was given 
to 90 patients with scleroderma and resulted in a 
6% treatment-related mortality, with four of the 
five deaths during the peritransplantation period 
attributable to cardiac complications.35 These data 
suggest that high-dose cyclophosphamide may be 
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too toxic for some patients with severe scleroder-
ma, particularly in the presence of heart disease.
In contrast to nonmyeloablative regimens, the 
conditioning regimen in the SCOT trial was de-
signed to maximally deplete T cells in both the 
graft and the host before progenitor-cell immune 
reconstitution. The unique property of total-
body irradiation to ablate dividing and resting 
autoreactive clones probably contributed to the 
durable remissions that we observed, findings 
that mirror those of preclinical transplantation 
studies in autoimmune disease.36 However, the 
mechanisms whereby immune homeostasis leads 
to control of autoimmune disease after autologous 
transplantation are yet to be fully elucidated.37-40
Our trial has limitations. We enrolled pa-
tients with severe internal organ disease and not 
solely skin disease, so results may not be gener-
alizable to all patients with scleroderma. The 
components of the global rank composite score 
and the hierarchy were chosen for this severely 
affected cohort and may not be generalizable to 
other populations. Although blinding is not pos-
sible in a transplantation trial, objective outcomes 
were placed higher in the global rank composite 
score hierarchy to mitigate this limitation.
In conclusion, at 54 months after random-
ization, myeloablative CD34+ selected autologous 
hematopoietic stem-cell transplantation resulted 
in significantly better clinical outcomes than 12 
months of cyclophosphamide. Although there was 
greater hematopoietic toxicity and an unquantified 
risk of second cancers from exposure to total-
body irradiation, toxic effects should be weighed 
against the beneficial results of treatment and 
the seriousness of the underlying disease.
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